Newsletter Signup | Join Community
Novel combination of sitravatinib and tislelizumab shows manageable safety and promising activity in phase Ib study
Maintenance therapy with Votrient delays cancer progression but does not appear to improve survival duration.
Genomic testing identifies genetic targets that can be treated with precision cancer medicines avoiding chemotherapy
PARPs and Avastin delay progression when used as maintenance therapy for certain individuals with ovarian cancer.
Understanding PARP inhibitor treatment in ovarian cancer - updated results from the Oct. ESMO 2019 meeting.
Lynparza is an effective treatment for women with newly diagnosed and recurrent BRCA + and other mutated ovarian cancers
Learn how to qualify for SS benefits.
Looking for Long Term Survivors: https://www.massgeneral…
Great NOCC overview on maintenance therapy for ovarian cancer. …
Speak up and share your story of hope!https://mavendoctors…